Lambert-Eaton Myasthenic Syndrome Clinical Trial
Official title:
Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3,4-Diaminopyridine Base (3,4-DAP) in Subjects With Known Lambert-Eaton Myasthenic Syndrome
Hypothesis: 3,4-Diaminopyridine base (3,4-DAP) improves Lambert-Eaton Myasthenic Syndrome (LEMS)-related weakness.
The objectives of the study were to confirm the safety and to test the efficacy of 3,4-DAP in
the treatment of LEMS-related weakness.
This was a phase 2 randomized double-blind placebo-controlled withdrawal study in subjects
with known clinically active LEMS who had been on a chronic stable dose of compassionate
distribution Jacobus 3,4-DAP provided through FDA-approved individual investigator-held INDs.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| No longer available |
NCT01373333 -
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
|
N/A | |
| Completed |
NCT02970162 -
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
|
Phase 3 | |
| Completed |
NCT05408702 -
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
|
||
| Completed |
NCT00004832 -
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
|
N/A | |
| No longer available |
NCT02189720 -
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
|
||
| Approved for marketing |
NCT00872950 -
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
|
||
| No longer available |
NCT00994916 -
Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
|